Published on : Aug 21, 2014
Novartis has signed a deal with the Global TB Alliance to handover its experimental tuberculosis medicine for further development and deployment, for no monitory gains it seems.
The deal is a clear indication how scrutiny over the company’s portfolio has been increased since Joerg Reinhardt took position as company’s new chairman. The new chairman is seen focusing more on the research of lucrative areas such as dermatology, cancer, respiratory drugs and heart failure.
While there is huge rush in the scientific community for discovering novel drugs for bacteria-infused diseases, it is also seen that many companies have already swayed away from this rush and moved their focus on more lucrative areas of drug discovery.
Under the deal, the TB Association will be responsible for further research, development, approvals and commercialization of the TB medicine initiated by Novartis.
WHO estimates that nearly 8.5 million people in the world fall sick with TB and nearly 1.3 million of them die every year.
Authorities of Novartis stated in an email that the goal of this agreement is solely to aid the program’s success and bring needed drugs to the patients. Also, the deal does not ask the TB Association to pay any kind of payment to Novartis.
Among the drug Novartis is dealing with the association is a class of drugs that targets multi resistant and drug resistant strains of TB. This class of drugs is called indolcarboxamides and it contains a compound, the NITD304, which helps in blocking a protein needed for the survival of the TB bacteria.
Authorities at Novartis have stated that the company is hopeful that the discoveries and compounds will be taken forward through more research and development by the TB Alliance.